Comprehensive Stock Comparison
Compare Moderna, Inc. (MRNA) vs Scinai Immunotherapeutics Ltd. (SCNI) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SCNI | 303.9% revenue growth vs MRNA's -53.3% |
| Quality / Margins | SCNI | 401.8% net margin vs MRNA's -140.3% |
| Stability / Safety | SCNI | Beta 0.60 vs MRNA's 1.25 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MRNA | +73.0% vs SCNI's -74.9% |
| Efficiency (ROA) | SCNI | 38.9% ROA vs MRNA's -25.7%, ROIC -61.1% vs -27.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Moderna is a biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines for infectious diseases, cancer, and other serious conditions. It generates revenue primarily from vaccine sales—notably its COVID-19 vaccine—with additional income from research collaborations and government grants. The company's key advantage is its proprietary mRNA technology platform, which enables rapid development of new vaccines and therapeutics compared to traditional methods.
Scinai Immunotherapeutics is a development-stage biopharmaceutical company focused on creating nanosized antibody therapies for infectious and autoimmune diseases. It generates revenue primarily through research collaborations and licensing agreements — notably with the Max Planck Society — while advancing its COVID-19 NanoAb and other pipeline candidates. The company's key advantage lies in its proprietary NanoAb platform technology, which aims to create smaller, potentially more effective antibody therapies compared to conventional antibodies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MRNA leads in 2 of 6 categories (Valuation Metrics, Total Returns). SCNI leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
MRNA is the larger business by revenue, generating $2.2B annually — 1936.4x SCNI's $1M. SCNI is the more profitable business, keeping 4.0% of every revenue dollar as net income compared to MRNA's -140.3%. On growth, SCNI holds the edge at +36.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MRNAModerna, Inc. | SCNIScinai Immunother… |
|---|---|---|
| RevenueTrailing 12 months | $2.2B | $1M |
| EBITDAEarnings before interest/tax | -$3.3B | -$7M |
| Net IncomeAfter-tax profit | -$3.1B | $5M |
| Free Cash FlowCash after capex | -$2.7B | -$6M |
| Gross MarginGross profit ÷ Revenue | +11.9% | -147.0% |
| Operating MarginEBIT ÷ Revenue | -155.9% | -7.4% |
| Net MarginNet income ÷ Revenue | -140.3% | +4.0% |
| FCF MarginFCF ÷ Revenue | -119.9% | -5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -45.2% | +36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.6% | +66.7% |
Valuation Metrics
| Metric | MRNAModerna, Inc. | SCNIScinai Immunother… |
|---|---|---|
| Market CapShares × price | $20.9B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $19.8B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | -5.78x | 0.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.55x | 4607.73x |
| Price / BookPrice ÷ Book value/share | 1.89x | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
SCNI delivers a 58.7% return on equity — every $100 of shareholder capital generates $59 in annual profit, vs $-33 for MRNA. MRNA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to SCNI's 0.21x. On the Piotroski fundamental quality scale (0–9), SCNI scores 5/9 vs MRNA's 4/9, reflecting solid financial health.
| Metric | MRNAModerna, Inc. | SCNIScinai Immunother… |
|---|---|---|
| ROE (TTM)Return on equity | -33.4% | +58.7% |
| ROA (TTM)Return on assets | -25.7% | +38.9% |
| ROICReturn on invested capital | -27.0% | -61.1% |
| ROCEReturn on capital employed | -28.9% | -63.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.07x | 0.21x |
| Net DebtTotal debt minus cash | -$1.2B | $122,000 |
| Cash & Equiv.Liquid assets | $1.9B | $2M |
| Total DebtShort + long-term debt | $747M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -393.13x | 3.35x |
Total Returns (with DRIP)
A $10,000 investment in MRNA five years ago would be worth $3,403 today (with dividends reinvested), compared to $20 for SCNI. Over the past 12 months, MRNA leads with a +73.0% total return vs SCNI's -74.9%. The 3-year compound annual growth rate (CAGR) favors MRNA at -27.2% vs SCNI's -66.5% — a key indicator of consistent wealth creation.
| Metric | MRNAModerna, Inc. | SCNIScinai Immunother… |
|---|---|---|
| YTD ReturnYear-to-date | +73.6% | +21.7% |
| 1-Year ReturnPast 12 months | +73.0% | -74.9% |
| 3-Year ReturnCumulative with dividends | -61.4% | -96.2% |
| 5-Year ReturnCumulative with dividends | -66.0% | -99.8% |
| 10-Year ReturnCumulative with dividends | +188.0% | -99.8% |
| CAGR (3Y)Annualised 3-year return | -27.2% | -66.5% |
Risk & Volatility
SCNI is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than MRNA's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRNA currently trades 97.0% from its 52-week high vs SCNI's 14.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MRNAModerna, Inc. | SCNIScinai Immunother… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 0.60x |
| 52-Week HighHighest price in past year | $55.20 | $6.18 |
| 52-Week LowLowest price in past year | $22.28 | $0.61 |
| % of 52W HighCurrent price vs 52-week peak | +97.0% | +14.4% |
| RSI (14)Momentum oscillator 0–100 | 71.6 | 52.3 |
| Avg Volume (50D)Average daily shares traded | 10.8M | 42K |
Analyst Outlook
| Metric | MRNAModerna, Inc. | SCNIScinai Immunother… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — |
| Price TargetConsensus 12-month target | $34.89 | — |
| # AnalystsCovering analysts | 27 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 100 | 142.4 | +42.4% |
| Scinai Immunotherap… (SCNI) | 100 | 0.12 | -99.9% |
Moderna, Inc. (MRNA) returned -66% over 5 years vs Scinai Immunotherap… (SCNI)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Moderna, Inc. (MRNA) | $108M | $3.2B | +2851.2% |
| Scinai Immunotherap… (SCNI) | $0.00 | $658000.00 | — |
Scinai Immunotherapeutics Ltd.'s revenue grew from $0M (2015) to $1M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Moderna, Inc. (MRNA) | -199.5% | -111.3% | +44.2% |
| Scinai Immunotherap… (SCNI) | 7.3% | 7.3% | +0.0% |
Moderna, Inc.'s net margin went from -199% (2016) to -111% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Moderna, Inc. (MRNA) | -3.79 | -9.27 | -144.6% |
| Scinai Immunotherap… (SCNI) | -396,880 | 6 | +100.0% |
Scinai Immunotherapeutics Ltd.'s EPS grew from $-396880.00 (2015) to $6.00 (2024).
Chart 5Free Cash Flow — 5 Years
Moderna, Inc. generated $-4B FCF in 2024 (-130% vs 2021). Scinai Immunotherapeutics Ltd. generated $-6M FCF in 2024 (+16% vs 2021).
MRNA vs SCNI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is MRNA or SCNI a better buy right now?
Scinai Immunotherapeutics Ltd. (SCNI) offers the better valuation at 0.1x trailing P/E, making it the more compelling value choice. Analysts rate Moderna, Inc. (MRNA) a "Hold" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MRNA or SCNI?
Over the past 5 years, Moderna, Inc. (MRNA) delivered a total return of -66.0%, compared to -99.8% for Scinai Immunotherapeutics Ltd. (SCNI). A $10,000 investment in MRNA five years ago would be worth approximately $3K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MRNA returned +188.0% versus SCNI's -99.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MRNA or SCNI?
By beta (market sensitivity over 5 years), Scinai Immunotherapeutics Ltd. (SCNI) is the lower-risk stock at 0.60β versus Moderna, Inc.'s 1.25β — meaning MRNA is approximately 107% more volatile than SCNI relative to the S&P 500. On balance sheet safety, Moderna, Inc. (MRNA) carries a lower debt/equity ratio of 7% versus 21% for Scinai Immunotherapeutics Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — MRNA or SCNI?
Scinai Immunotherapeutics Ltd. (SCNI) is the more profitable company, earning 728.9% net margin versus -111.3% for Moderna, Inc. — meaning it keeps 728.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRNA leads at -123.3% versus -1312.8% for SCNI. At the gross margin level — before operating expenses — MRNA leads at 54.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — MRNA or SCNI?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is MRNA or SCNI better for a retirement portfolio?
For long-horizon retirement investors, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.60)). Both have compounded well over 10 years (SCNI: -99.8%, MRNA: +188.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between MRNA and SCNI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: MRNA is a mid-cap quality compounder stock; SCNI is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.